Entera Bio (ENTX) Cash & Equivalents (2017 - 2026)

Entera Bio (ENTX) has 10 years of Cash & Equivalents data on file, last reported at $4.1 million in Q1 2026.

• Quarterly Cash & Equivalents fell 67.1% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 67.1% YoY) and the FY2025 annual result came in at $7.1 million, down 17.92% from the prior year.
• Cash & Equivalents declined to $4.1 million in Q1 2026, from $7.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $20.1 million in Q1 2022 to a low of $4.1 million in Q1 2026.
• A 5-year average of $10.6 million and a median of $9.2 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2025 — Cash & Equivalents jumped 36.83% — and 2026, when it sank 67.1%.
• Tracing ENTX's Cash & Equivalents over 5 years: stood at $12.3 million in 2022, then dropped by 10.48% to $11.0 million in 2023, then fell by 21.41% to $8.7 million in 2024, then declined by 17.92% to $7.1 million in 2025, then sank by 41.8% to $4.1 million in 2026.
• The last three Cash & Equivalents figures came in at $4.1 million (Q1 2026), $7.1 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.